P

Inventor

FERRARA MARCO

IT46 patents
⚠️ This page may combine multiple inventors who share the name “FERRARA MARCO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BOEHRINGER INGELHEIM INT

17 patents
US10183940B2Jan 22, 2019

Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists

BOEHRINGER INGELHEIM INT2 citations73
US10071974B2Sep 11, 2018

Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists

BOEHRINGER INGELHEIM INT2 citations73
US10875867B2Dec 29, 2020

Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

BOEHRINGER INGELHEIM INT3 citations72
US10479794B2Nov 19, 2019

Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

BOEHRINGER INGELHEIM INT3 citations72
US9884854B2Feb 6, 2018

N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides

BOEHRINGER INGELHEIM INT6 citations71
US12351584B2Jul 8, 2025

Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

BOEHRINGER INGELHEIM INT0 citations62
US11691977B2Jul 4, 2023

Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide

BOEHRINGER INGELHEIM INT0 citations62
US10577336B2Mar 3, 2020

Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists

BOEHRINGER INGELHEIM INT1 citations62
US10023575B2Jul 17, 2018

Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

BOEHRINGER INGELHEIM INT1 citations62
US11780827B2Oct 10, 2023

Substituted 3-phenoxyazetidin-1-yl-pyrazines

BOEHRINGER INGELHEIM INT1 citations59
US11236072B2Feb 1, 2022

N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides

BOEHRINGER INGELHEIM INT0 citations59
US10787432B2Sep 29, 2020

N-[(pyridyloxy)propanyl]benzamides

BOEHRINGER INGELHEIM INT0 citations50
US10738031B2Aug 11, 2020

N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity

BOEHRINGER INGELHEIM INT0 citations50
US10710984B2Jul 14, 2020

N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides

BOEHRINGER INGELHEIM INT0 citations50
US10604511B2Mar 31, 2020

N-[(pyrazinyloxy)propanyl]benzamides as antagonists of orexin subtype 1 receptor activity

BOEHRINGER INGELHEIM INT0 citations50
US10392369B2Aug 27, 2019

N-[(pyrimidinyloxy)propanyl]benzamides

BOEHRINGER INGELHEIM INT0 citations50
US12115157B2Oct 15, 2024

3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

BOEHRINGER INGELHEIM INT0 citations46

FORM ENERGY INC

9 patents

IHI INC

5 patents

CENTREXION THERAPEUTICS CORP

3 patents

IHI TERRASUN SOLUTIONS INC

2 patents

MERCK SHARP & DOHME

1 patent

HARPER STEVEN

1 patent

CT XION THERAPEUTICS CORP

1 patent

HEINE NIKLAS

1 patent

GIOVANNINI RICCARDO

1 patent

C/O FORM ENERGY INC

1 patent

CRESCENZI BENEDETTA

1 patent

MICRON TECHNOLOGY INC

1 patent

PASQUALE CIMMINO

1 patent

ANTIOS THERAPEUTICS INC

1 patent